BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 12, Issue 531, Pages eaax2625
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-02-20
DOI
10.1126/scitranslmed.aax2625
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
- (2019) Junko Murai et al. PHARMACOLOGY & THERAPEUTICS
- Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer
- (2019) Edoardo Isnaldi et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Topoisomerase I in the Era of Precision Medicine
- (2019) Anish Thomas et al. CLINICAL CANCER RESEARCH
- The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination–Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
- (2019) Laetitia Marzi et al. CLINICAL CANCER RESEARCH
- Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
- (2018) Elisabetta Marangoni et al. CLINICAL CANCER RESEARCH
- Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11)Expression with Class I Histone Deacetylase Inhibitors
- (2018) Sai-Wen Tang et al. CLINICAL CANCER RESEARCH
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors
- (2018) Laetitia Marzi et al. MOLECULAR CANCER THERAPEUTICS
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Expression of MT4-MMP, EGFR and RB in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy
- (2018) Pierre Foidart et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
- (2017) Robert W Mutter et al. JOURNAL OF PATHOLOGY
- Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors
- (2016) Shivaani Kummar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
- (2016) Yves Pommier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
- (2015) M. H. Kang et al. CLINICAL CANCER RESEARCH
- SLFN11 inhibits checkpoint maintenance and homologous recombination repair
- (2015) Y. Mu et al. EMBO REPORTS
- Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
- (2015) Julie L. Boerner et al. PLoS One
- Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
- (2014) Agnieszka K Witkiewicz et al. BREAST CANCER RESEARCH
- A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
- (2013) Iben Kümler et al. BREAST CANCER RESEARCH AND TREATMENT
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents
- (2011) Kristy R. Stengel et al. CELL CYCLE
- RB-pathway disruption in breast cancer
- (2010) Adam Ertel et al. CELL CYCLE
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
- (2010) Yves Pommier et al. CHEMISTRY & BIOLOGY
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays
- (2009) Tatiana Popova et al. GENOME BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started